XPRESS MAIL NO. EV335394085US

JUN 3 0 2004

07-02 04

**TRANSMITTAL FORM** 

(To be used for all correspondence after initial filing)

Application Manager	09/593,793		Y
Filing Date	June 13, 2000		
First Named Inventor	Jiangchun Xu	JUI 082	nna
Art Unit	1642		700
Examiner Name	David J. Blanchard	TECH CENTER 10	nn maan
Attorney Docket No.	210121.427C15	enderstein 66	AM CHÁN

ENCLOSURES (check all that apply)								
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Sixth Supplemental Information Disclosure Statement; Form PTO-1449 S Cited References Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund	CD(s), Number of CD(s)  After Allowance Communication to Technology Center (TC)' Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):						
Remarks								
SIGNATUR	RE OF APPLICANT, ATTORNEY,	OR AGENT						
Individual Name Jeffrey E. Hu Reg. No. 42,6	Customer Number 00500							
Signature								
Date June 30, 2004								
CERTIFICATE OF TRANSMISSION/MAILING  I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited' with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.								
Typed or printed name								
Signature		Date:						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



JUL 0 8 2004

## **EXPRESS MAIL NO. EV335394085US**



**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Jiangchun Xu et al.

Application No.

09/593,793

Filed

June 13, 2000

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF PROSTATE CANCER

Examiner

: David J. Blanchard

Art Unit

: 1642

Docket No.

210121.427C15

Date

: June 30, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 CFR 1.98, are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We hereby certify that each of the references set forth on the attached form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

Please acknowledge receipt of this Sixth Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Jeffrey Hundley, Ph.D., Patent Agent

Registration No. 42,676

JEH:ljt

**Enclosures:** 

Postcard Transmittal Form Form PTO-1449 Cited References (5)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\494462

FORM PTO-1449	)	U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO. APPLICATION NO.					
(REV.7-80) PATENT AND TRADEMARK OFFICE			210121.427C15 09/593,793							
SIXTH SUPPLEMENTAL			APPLICANTS							
INFORMATION DISCLOSURE STATEMENT			Jiangchun Xu et al.							
JUN 30 S	טטיי ט	(Use several sheets if neces	essary)		FILING DATE			UP ART UNIT		
•		<u>/</u>		June 13, 2000			1642 <b>J</b> U		08 2004	
U.S. PATENT DOCUMENTS										
*EXAMINER						TECH CEN			ER-1600/2900E	
· INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS		SUBCLASS	IF APPROP	
	AA									
-										
	AB			-				· · · · · · · · · · · · · · · · · · ·		-
	AC									
	AD									
	1.2									
	AE									
	AF									
	AG							<u></u>		
:			FOREIGN PA	ATE	NT DOCUMENTS					
		DOCUMENT	DATE		COUNTRY				TRANS	LATION
		NUMBER	DATE		- COUNTRI				YES	NO
	AK									
	AL				•					
	AL									
	AM									
		ОТИБ	D DDIOD ADT a	, ,.	4 .1					
	1 1				g Author, Title, Date, Pertinent Pa					
	AP		Aspinall, J.O. et al., "Differential Expression of Apolipoprotein-D and Prostate Specific							
			Antigen in Benign and Malignant Prostate Tissues," Journal of Urology 154: 622-628,							
		August 1996.	August 1996.							
	AQ	Fannon, M.R	., "Gene expression	n in	normal and disease star	tes – i	dent	ification of	fthera	peutic
		targets," Trends in Biotechnology 14: 294-298, August 1996.								
	AR	Garde, S.V. e	t al., "Prostate inh	nibin	peptide (PIP) in prostat	te can	cer:	a compara	tive	
					rostate-specific antigen			_		
		phosphatase (	PAP)," Cancer L	etter:	s 78: 11-17, 1994.	` /		•		
					AA112574, May 29, 20	003.				
			,		· · · · · · · · · · · · · · · · · · ·					
		Murphy G e	t al., "Comparisor	n of I	Prostate Specific Memb	rane A	\ ntic	en and Pr	Ostate	
•		1			Cancer Patients," Anti			_		ı
		1995.	Peri Tevers III I 10:	naii	Cancer ranems, Ann	cunce	, NE	scuren 15.	17/3-	1700,
EXAMINE	ER	1993.			DATE CONSIDERED					
DATE CONSIDERED										
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in										
					with next communication to applic		-			